Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Finished Goods (2016 - 2022)

Historic Finished Goods for Usana Health Sciences (USNA) over the last 12 years, with Q3 2022 value amounting to $51.5 million.

  • Usana Health Sciences' Finished Goods fell 413.8% to $51.5 million in Q3 2022 from the same period last year, while for Jul 2022 it was $51.5 million, marking a year-over-year decrease of 413.8%. This contributed to the annual value of $58.5 million for FY2022, which is 1253.75% up from last year.
  • Per Usana Health Sciences' latest filing, its Finished Goods stood at $51.5 million for Q3 2022, which was down 413.8% from $57.3 million recorded in Q2 2022.
  • In the past 5 years, Usana Health Sciences' Finished Goods registered a high of $58.5 million during Q1 2022, and its lowest value of $36.6 million during Q1 2020.
  • For the 5-year period, Usana Health Sciences' Finished Goods averaged around $47.8 million, with its median value being $48.7 million (2018).
  • In the last 5 years, Usana Health Sciences' Finished Goods surged by 4223.31% in 2018 and then tumbled by 3013.33% in 2020.
  • Over the past 5 years, Usana Health Sciences' Finished Goods (Quarter) stood at $48.0 million in 2018, then fell by 14.69% to $40.9 million in 2019, then grew by 15.12% to $47.1 million in 2020, then grew by 16.78% to $55.0 million in 2021, then fell by 6.3% to $51.5 million in 2022.
  • Its last three reported values are $51.5 million in Q3 2022, $57.3 million for Q2 2022, and $58.5 million during Q1 2022.